SUMMARY
Day case surgery provides anaesthetists with the dual challenge of providing good pain relief while minimizing side-effects, in order that prompt mobilization and discharge from hospital are possible. Furthermore, in the post discharge, "at home" setting, analgesia must be both adequate and longlasting, so that there are minimal demands on community health services and rapid patient recovery to preoperative fitness is promoted.
Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) have both been extensively used for laparoscopic day case procedures. Use of NSAIDs may reduce the unwanted side-effects of nausea, vomiting and sedation or the more serious problem of respiratory depression that is generally associated with opioid analgesia. Avoiding these adverse effects is particularly important in day case surgery because any or all of these side-effects may delay discharge. NSAIDs may have a specific advantage in tubal surgery as local prostaglandin release is associated with pain after these procedures 1, 2 . Ketorolac, an injectable NSAID, has been reported to be comparable with pethidine 3 and morphine 4, 5 when used as a postoperative analgesic. Its use in laparoscopy by bolus dose has resulted in reduced recovery time 6 , lower pain scores 7 and a lower incidence of side-effects 8 . However, these findings have not been consistent, with some studies reporting no difference from placebo 9, 10 . Following laparoscopic surgery the most severe pain occurs during the first 24 hours, coinciding with continuing release of inflammatory mediators including prostaglandins. We hypothesized that suppression of these mediators during this period could have a significant impact on the patient's overall rate of recovery. We carried out a randomized, double-blind, placebo-controlled study to test this hypothesis. For 24 to 36 hours postoperatively, ketorolac was administered by subcutaneous infusion, in order to ensure round-the-clock drug delivery.
Patients were followed up for four days postoperatively to determine any impact on the rate of return to normal function, compared to patients receiving only oral opioid analgesia.
MATERIALS AND METHODS
This study was approved by our hospital Ethics Committee. Informed consent was sought from women aged 18 to 50 years and weighing 50 to 90 kg who presented at Flinders Medical Centre (FMC) for elective day case laparoscopic procedures. Patients with any contraindication to ketorolac or codeine, those taking analgesic or potentially nephrotoxic drugs, patients with a history of overdose, those with severe systemic disease (ASA 3 or more) or with a history of asthma were excluded.
Patients were randomly assigned to "ketorolac" or "control" groups according to computer-generated randomization lists. Randomization was stratified according to the scheduled laparoscopic procedure. Group DL included those having diagnostic laparoscopy only, group TL laparoscopic tubal ligation and group LS laparoscopic surgery involving electrocautery or laser surgery. The randomization code was kept by the Department of Pharmacy who supplied study drugs for each patient. Patients and investigators were blinded to the nature of the study drug.
The anaesthetic was standardized, all patients receiving propofol, fentanyl (1.5 µg/kg), vecuronium, oxygen and nitrous oxide, isoflurane and an intravenous fluid load of Hartmann's solution of at least 10 ml/kg. At the end of the procedure the laparoscopy portals were infiltrated with 5 to 10 ml of bupivacaine 0.5%.
After release of the pneumoperitoneum, a bolus dose of 3 ml of the study drug solution containing ketorolac 10.5 mg, or an equivalent volume of saline was administered via a 22 gauge Insyte TM cannula inserted subcutaneously in the right or left subclavian area. A disposable infusion device (Multiday Infusor 0.5 ml/h, Baxter Healthcare Corporation, Deerfield IL) was then used to administer an infusion of either ketorolac 1.75 mg/h or saline through the cannula.
In the Recovery Ward, fentanyl was administered intravenously for pain control. Total dose of fentanyl given, severity of nausea (0=none; 1=present but no treatment required; 2=present but responds to treatment; 3=persists in spite of treatment) and vomiting (number of episodes) were recorded. After recovery, patients were transferred to the Day Stay Unit (DSU). Nausea, vomiting and number of codeine tablets given in the DSU were recorded prior to discharge. Patients were discharged with analgesia in the form of codeine phosphate 30 mg tablets, with instructions to take one or two tablets every four hours if required for pain.
Following discharge, a research nurse visited the patients 24 to 36 hours postoperatively to remove the infusion device and inspect the infusion site. Patients completed a diary each evening for the first four postoperative days. They were asked to quantify discomfort (0=no discomfort, 1=discomfort, 2=cannot perform activity due to discomfort) while performing the following activities: getting out of bed; rising from a chair; standing from a squatting position; walking inside the house; walking outside the house; performing heavy work like running, sweeping, vacuuming or carrying children. Patients also recorded pain, nausea, drowsiness and headache (0=none, 1=mild, 2=moderate, 3=severe) as well as the number of episodes of vomiting and number of codeine tablets taken each day. The nurse visited the patient again five to seven days postoperatively to collect the diary.
Number of Patients
Sample size was based on results of an earlier study of pain control following laparoscopic surgery 11 . In that study, patients recorded a pain score from 0 (none) to four (unbearable) at 0800 h and 2000 h daily for seven days postoperatively. From the data obtained, we determined the time until patients reported the first pain score of 0. This was used as a surrogate variable on the basis that freedom from pain would be associated with absence of discomfort on performing the activities. It was determined that a total of 72 patients would provide 80% power at a type 1 error of 0.05 to detect a reduction of one day in time to freedom from pain.
Data Analysis
All data analyses were carried out blindly-the two treatment groups were labelled A and B. Only after analyses were complete and conclusions about group differences drawn was the code completely broken. The discomfort scores of each patient for the six activities were summed on each day to provide a global discomfort score for that day. Global discomfort scores, fentanyl dose, pain scores, side-effect severity scores and number of codeine tablets consumed were analysed by ordinal logistic regression independent between patients, but not within patients. To allow for non-independence within patients, standard errors of the parameter estimates were obtained from Huber/ White/sandwich variance estimates 13 with each patient treated as a cluster.
RESULTS
Seventy-seven patients were enrolled to provide 72 evaluable patients. Of the five patients who were withdrawn, one withdrew consent prior to surgery, while the surgical procedures for the other four were done as open procedures. None of the withdrawn patients received any study medication. Characteristics of patients in the ketorolac and placebo groups were similar ( Table 1) . 
Recovery
In the Recovery Ward, nausea scores, incidence of vomiting, and antiemetic administration were similar in the two groups. The placebo group, however, received significantly more fentanyl (median 80 µg) than the ketorolac group (median 40 µg) (P=0.016). The amount of fentanyl given did not differ significantly among surgery types (P>0.7).
Day Stay Unit
In the DSU, nausea scores, incidence of vomiting and administration of antiemetic were similar for the two groups. The amount of codeine administered was significantly greater in the placebo group (median 1 tablet) compared with the ketorolac group (median 0 tablets) (P=0.005) ( Table 2 ). Twenty-nine of the 39 patients in the placebo group compared to 13 of the 33 patients in the ketorolac group were given codeine in the DSU. The distribution of pain scores prior to discharge was similar in the two groups (Table 3) .
Postoperative Period After Discharge
At the time of removal of the infusion device, no patients were noted to have experienced any irritation, swelling or abnormal pain at the infusion site. On postoperative day 1 the placebo group consumed significantly (P=0.028) more codeine (median, three tablets) than the ketorolac group (median, one tablet) ( Table 2 ). Despite this, pain scores in the placebo group were higher (median 2.0) than those of the ketorolac group (median 1.0), though the difference did not achieve statistical significance (P=0.052). Scores for severity of nausea, vomiting, drowsiness and headache did not differ between the groups (all P>0.2). Discomfort scores did not differ significantly between ketorolac and placebo groups on day 1 (P=0.15) (Figure 1 ). Over the four-day postoperative period, there was a significant decline in codeine consumption (P<0.001), and an overall higher level of consumption in the placebo group compared with the ketorolac group (P=0.01) ( Table 2) . Pain, nausea, vomiting, drowsiness and headache severity scores all declined significantly over the four days (P 0.002), but did not differ significantly between placebo and ketorolac groups (P>0.4).
Discomfort scores declined over the four postoperative days (P<0.001) and there was no overall difference between ketorolac and placebo groups (P=0.37) (Figure 1 ). Discomfort scores were lower in the DL (P=0.048) and TL (P=0.049) groups compared to the LS group (Figure 2) . This difference was not apparent, however, on Day 1, when median discomfort scores were 7 for all three surgical groups.
Ability to perform activities without discomfort improved over the four-day period, although some activities involved less discomfort than others ( Figure  3) . Walking inside the house and walking outside the house were associated with the least discomfort, whereas heavy work was associated with the most discomfort. Three days postoperatively about 50% of patients could perform most of the activities assessed without discomfort, though even after four days only 38% were free of discomfort when performing heavy work.
DISCUSSION
The use of NSAIDs in the postoperative period has a number of benefits. NSAIDs have an opioid-sparing effect, facilitate recovery after more extensive ambulatory surgery and are associated with a low incidence of emesis. The majority of studies, however, have concentrated on the early postoperative phase and little is known of the recovery period after discharge.
This study tested the hypothesis that administration of a subcutaneous ketorolac infusion would improve analgesia in the first 24 to 36 hours, and would have a beneficial effect on patient recovery over the subsequent postoperative days. We chose to use a subcutaneous infusion because the study aimed to evaluate the efficacy of ketorolac in this setting and we felt that this mode of administration would optimize the likelihood of identifying any benefit. It was not considered that this procedure would be suitable for routine clinical use following day surgery.
The results obtained failed to confirm the hypothesis. Patient description of discomfort on performing six separate activities at home did not indicate any beneficial effect of ketorolac, on either day 1 or over the whole four-day postoperative period. This was despite the ketorolac group requiring significantly less fentanyl in the Recovery Ward, and significantly less codeine prior to and following discharge. A reduction in opioid requirement might in itself be beneficial if it resulted in reduced sideeffects; however our results did not demonstrate this. Likewise, while there may have been a marginal Discharge  13  19  1  0  14  22  3  0  Day 1  3  20  9  1  1  18  17  3  Day 2  5  20  7  1  4  25  10  0  Day 3  7  23  3  0  13  24  2  0  Day 4  20  12  1  0  20 benefit in terms of improved analgesia on the first postoperative day, subsequent pain scores in the two groups were similar. The opioid-sparing effect of NSAIDs is well documented [14] [15] [16] [17] [18] [19] [20] and in this study the effect outlasted the period of administration of the NSAID. The reduced consumption of codeine by the ketorolac group might be interpreted as indicating a reduced need for analgesia, but this is not supported by the pain score data, which showed similar levels of pain in the two groups after cessation of the study drug infusion. Furthermore, it seems unlikely that the ketorolac would have had a pre-emptive analgesic effect as it was commenced near the end of surgery. Since the elimination half-life of ketorolac is four to six hours and its metabolites have minimal activity 21 , it is also unlikely that there were residual effects of ketorolac in the days following the infusion. We speculate that the continued higher codeine consumption in the placebo group was due to a "learned drug-taking" behaviour. That is, during the early postoperative period patients receiving placebo medication may have "learned" that they required a high codeine consumption to obtain analgesia and may have continued this pattern of consumption throughout the postoperative period. The ketorolac group, on the other hand, having required fewer tablets in the early phase, became accustomed to a low consumption level.
The scoring system of assessing function used in this study measured discomfort on performing six activities in the home setting. As expected, function improved over the four-day postoperative period. Furthermore, we were able to demonstrate significant differences in function of patients following diagnostic laparoscopy or tubal ligation, as opposed to the presumably more traumatic surgery involving laser or electrocautery.
It is noteworthy that many patients reported discomfort performing everyday activities even on the fourth postoperative day. Almost a quarter still had discomfort when walking inside the house, which was the activity associated with the least discomfort. On day 4, 58% of patients still had discomfort on performing heavy work, which for our purposes consisted of ordinary daily activities such as vacuuming and carrying children, while 4% still could not carry out these activities. Day surgery may have short-term benefits to health care providers in terms of decreased cost and increased turnover, but its benefits are not being fully realised. The impairment of function that follows these minor surgical procedures has major economic as well as humanitarian implications for the community. Our results suggest that provision of additional analgesia by itself may not be adequate to hasten return of normal function. More knowledge is required about the causes of this impairment so that appropriate actions can be taken to reduce it.
